Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immunotherapy of cancer

2822 - Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C

Date

11 Sep 2017

Session

Immunotherapy of cancer

Presenters

Rajat Rai

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

R. Rai1, O.M. Ezeoke2, J.L. McQuade3, L. Zimmer4, C. Koo5, J.J. Park6, L. Ardolino7, D. Yip8, S. Goldinger9, J.V. Cohen10, M. Millward11, V. Atkinson12, A.Y. Kane13, P.A. Ascierto14, C. Garbe15, R. Gutzmer16, D.B. Johnson17, M.D. Hellman18, G.V. Long19, A.M. Menzies19

Author affiliations

  • 1 Melanoma Oncology, Melanoma Institute Australia, The University of Sydney, 2060 - Sydney/AU
  • 2 Department Of Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 3 Department Of Medicine, MD Anderson Cancer Center, 77030 - Houston/US
  • 4 Department Of Dermatology, University Hospital, University Duisburg-Essen, 47057 - Duisburg/DE
  • 5 Department Of Oncology, Peter MacCallum Cancer Care Centre, 3000 - melbourne/AU
  • 6 Department Of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, 2145 - Westmead/AU
  • 7 Medical Oncology, Saint Vincent's Hospital, 2010 - Sydney/AU
  • 8 Department Of Medical Oncology, The Canberra Hospital, 2605 - Garran/AU
  • 9 Department Of Dermatology, University Hospital Zürich-Dermatology, 8091 - Zürich/CH
  • 10 Department Of Oncology, Massachusetts General Hospital, 2114 - Boston/US
  • 11 Department Of Medical Oncology, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, 6009 - Nedlands/AU
  • 12 Department Of Medical Oncology, Princess Alexandra Hospital, 4102 - Woolloongabba/AU
  • 13 Department Of Immunology, Liverpool Hospital and Garvan Institute of Medical Research, Sydney/AU
  • 14 Melanoma, Cancer Immunotherapy And Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione Pascale, 80131 - Napoli/IT
  • 15 Department Of Dermatology, University of Tuebingen-Dermatology, 72076 - Tübingen/DE
  • 16 Department Of Dermatology, Hannover Medical School, Klinik für Dermatologie, Allergologie und Venerologie, 30449 - Hannover/DE
  • 17 Medical Oncology, Vanderbilt Ingram Cancer Center, 37232 - Nashville/US
  • 18 Department Of Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 19 Melanoma Medical Oncology, Melanoma Institute Australia (MIA) and Royal North Shore Hospital, The University of Sydney, Sydney/AU
More

Resources

Abstract 2822

Background

Anti PD-1/L1 (PD1) agents are being used to treat various tumor types. Most trials have excluded patients (pts) who have had a solid organ transplant (SOT), HIV, or Hepatitis (Hep) B and Hepatitis C. The safety and efficacy of PD1 in this setting is unknown.

Methods

Pts treated at 16 centres that had a transplant, HIV, Hep B/C were included. Patient demographics, tumour characteristics, toxicity, response and survival data, and the effect on the underlying condition were collected.

Results

42 pts were identified; 29 with melanoma, 6 bladder carcinoma (BC), 2 hepatocellular carcinoma (HCC), 2 renal cell carcinoma (RCC), 2 mesothelioma (meso), and 1 each of gastric carcinoma, glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). 5 pts with SOT (4 renal,1 liver) had melanoma received pembrolizumab; 3 had progressive disease (PD), 1 partial response (PR), and the pt with liver transplant had graft rejection and died from this after 1 dose. 11 pts had HIV; 2 with detectable viral load. 8 pts had pembrolizumab (7 melanoma, 1 HCC), 2 nivolumab (1 melanoma, 1 RCC) and 1 atezolizumab (BC). No pt had loss in viral control or immune reconstitution inflammatory syndrome. 2 had complete response (CR), 1 PR, 4 stable disease (SD) and 4 PD. 14 pts had Hep C; 9 with detectable viral load, 6 on anti-viral therapy and 5 with cirrhosis. 6 received pembrolizumab (5 melanoma, 1 meso), 7 nivolumab (4 melanoma, 1 each of NSCLC, BC, RCC) and 1 atezolizumab (BC). No pt had loss in viral control, 1 developed grade 3 colitis but no one developed hepatitis. 2 had CR, 9 SD and 3 PD. 12 pts with Hep B; 8 with detectable viral load, 6 on anti-viral therapy and none with cirrhosis. 8 had pembrolizumab (5 melanoma, 1 each of GBM, gastric carcinoma and meso), 4 nivolumab (2 melanoma, 1 BC, 1 HCC). No pt had loss in viral control.1 had CR, 1 PR, 8 SD and 2 PD. None of Hep B or Hep C pts developed immune related hepatits.

Conclusions

Immunotherapy appears to have activity in patients with SOT, HIV and Hep B and Hep C. It can be given to renal transplant pts without rejection, however this is not universal . PD1 does not appear to adversely affect the viral control in HIV and Hep B and Hep C pts.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Human ethics approved protocol at Melanoma Institute Australia

Funding

None

Disclosure

L. Zimmer: Honoraria: Roche. S. Goldinger: Research funding from the Zurich University Hospital and received travel grant support from Novartis, Roche, MSD and Bristol-Myers Squibb. An intermittent advisory board relationship with Novartis, Roche, MSD and Bristol-Myers Squibb. M. Millward: grant support from GlaxoSmithKline during the conduct of the study and other support from GlaxoSmithKiline. V. Atkinson: advisory boards and received travel support and speaker\'s fees from Bristol-Myers Squibb, Novartis and MSD. GVL is a consultant advisor to Amgen, Merck MSD, Novartis and Roche received honoraria from Bristol-Myers Squibb, Novartis and Merck MSD. P.A. Ascierto: receiving consulting fees from Bristol-Myers Squibb, Roche, GSK, MSD, Ventana Medical Systems, Novartis, and Amgen, honoraria from Bristol-Myers Squibb, Roche, and GSK, and grant support to his institution from Bristol-Myers Squibb, Roche, and Ventana Medical Systems; C. Garbe: Advisory board: AMGEN, Bristol-Myers Squibb, GSK, MSD, Novartis and Roche Lecture honorarium: Bristol-Myers Squibb, MSD Consulting: Roche. R. Gutzmer: Received project support from Novartis Pharma and Pfizer Lecture honoraria from Novartis Pharma and Pfizer. D.B. Johnson: personal fees from Genoptix and Bristol-Myers Squibb. G.V. Long: personal fees from GlaxoSmithKline during the conduct of the study and personal fees from Roche, Novartis, Amgen, and Bristol Myers Squibb. A.M. Menzies: honoraria from Bristol-Myers Squibb and Novartis, and has sat on advisory boards for MSD and Chugai All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.